Cited 0 times in
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세헌 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최은창 | - |
dc.contributor.author | 고윤우 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 김건민 | - |
dc.contributor.author | 김한상 | - |
dc.contributor.author | 김선미 | - |
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2014-12-19T16:36:56Z | - |
dc.date.available | 2014-12-19T16:36:56Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89863 | - |
dc.description.abstract | PURPOSE: To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. METHODS: A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m(2) on days 1-14 and with cisplatin 70 mg/m(2) on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. RESULTS: The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. CONCLUSIONS: The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a first-line chemotherapy regimen for advanced head and neck squamous cell carcinoma patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Carcinoma, Squamous Cell/pathology | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Head and Neck Neoplasms/drug therapy* | - |
dc.subject.MESH | Head and Neck Neoplasms/mortality | - |
dc.subject.MESH | Head and Neck Neoplasms/pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy | - |
dc.subject.MESH | Oxonic Acid/administration & dosage* | - |
dc.subject.MESH | Oxonic Acid/adverse effects | - |
dc.subject.MESH | Tegafur/administration & dosage* | - |
dc.subject.MESH | Tegafur/adverse effects | - |
dc.title | The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Han Sang Kim | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Yoon Woo Koh | - |
dc.contributor.googleauthor | Se Hun Kim | - |
dc.contributor.googleauthor | Eun Chang Choi | - |
dc.contributor.googleauthor | Yun Kyoung Hong | - |
dc.contributor.googleauthor | Ji Hee Sung | - |
dc.contributor.googleauthor | Sun Mi Kim | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 22868340 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00605 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04161 | - |
dc.contributor.localId | A00133 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A00546 | - |
dc.contributor.localId | A01098 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 22868340 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-012-1933-8 | - |
dc.subject.keyword | Head and neck cancer | - |
dc.subject.keyword | S-1 | - |
dc.subject.keyword | Cisplatin | - |
dc.subject.keyword | Recurrent | - |
dc.subject.keyword | Metastatic | - |
dc.contributor.alternativeName | Kim, Se Heon | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Eun Chang | - |
dc.contributor.alternativeName | Kho, Yoon Woo | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.alternativeName | Kim, Han Sang | - |
dc.contributor.alternativeName | Kim, Sun Mi | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Kim, Se Heon | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Eun Chang | - |
dc.contributor.affiliatedAuthor | Kho, Yoon Woo | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Kim, Sun Mi | - |
dc.contributor.affiliatedAuthor | Kim, Han Sang | - |
dc.citation.volume | 70 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 539 | - |
dc.citation.endPage | 546 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.70(4) : 539-546, 2012 | - |
dc.identifier.rimsid | 31951 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.